Formulation and evaluation of Ketorolac tromethamine for transdermal drug delivery system

Rajini Kanth Giddam 1, * and K AnieVijetha 2

1 Department of Pharmaceutics, Vijaya College of Pharmacy, Munaganoor, Hayathnagar, Hyderabad, Telangana-500085, INDIA.
2 Department Pharmaceutics, Centre for Pharmaceutical Sciences, Institute of Science and Technology, JNTUH.
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 22(03), 153–162.
Article DOI: 10.30574/gscbps.2023.22.3.0085
Publication history: 
Received on 18 January 2023; revised on 15 March 2023; accepted on 18 March 2023
 
Abstract: 
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Ketorolac Tromethamine are widely recommended to treat pain caused by osteoarthritis, ankylosing spondylitis, acute sciatica, rheumatoid arthritis and low back pain. Modern drug delivery technology, such as transdermal patches, is mostly used in the treatment of numerous diseases. As first-pass metabolism is avoided. Transdermal drug delivery systems (TDDS) can efficiently enhance bioavailability and help with the planned and controlled release of drug molecules into the systemic circulation. The purpose of this work was to produce matrix-type Ketorolac tromethamine transdermal patches by solvent evaporation using different polymer ratios, such as HPMC 15 cps, HPMC E5, and Eudragit S 100. Along with solvents like methanol and chloroform, plasticizers like glycerine, propylene glycol, and PEG 200 are used in this formulation. According to the FTIR study, Ketorolac Tromethamine had no significant interactions with other excipients. The following evaluations are carried out such as thickness, weight variation, folding durability, moisture content, drug content, surface pH, and In vitro diffusion are all evaluated for the prepared patches.
 
Keywords: 
Transdermal drug delivery system; Ketorolac tromethamine; HPMC 15cps; Eudragit S100; HPMC E5
 
Full text article in PDF: 
Share this